Profile data is unavailable for this security.
About the company
TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.
- Revenue in USD (TTM)0.00
- Net income in USD-17.91m
- Incorporated2016
- Employees10.00
- LocationTranscode Therapeutics Inc6 Liberty Square, #2382BOSTON 02109United StatesUSA
- Phone+1 (857) 301-6857
- Fax+1 (302) 655-5049
- Websitehttps://www.transcodetherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Weed Inc | 0.00 | 57.30k | 5.31m | 2.00 | 84.31 | 706.08 | 61.40 | -- | 0.0005 | 0.0005 | 0.00 | 0.00006 | 0.00 | -- | -- | 0.00 | 6.00 | -385.93 | -- | -822.37 | -- | -- | -- | -- | -- | -46.08 | 0.944 | -- | -- | -- | 97.93 | -- | -59.13 | -- |
Burzynski Research Institute Inc | 0.00 | -1.42m | 5.40m | 2.00 | -- | -- | -- | -- | -0.0108 | -0.0108 | 0.00 | -0.001 | 0.00 | -- | -- | -- | -153,444.30 | -15,304.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -45.74 | -- | -- | -- |
Virios Therapeutics Inc | 0.00 | -5.30m | 5.53m | 4.00 | -- | 1.76 | -- | -- | -0.2603 | -0.2603 | 0.00 | 0.113 | 0.00 | -- | -- | 0.00 | -119.71 | -79.80 | -135.31 | -89.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 56.76 | -- | -- | -- |
ELEVAI Labs Inc | 2.47m | -4.75m | 5.65m | 18.00 | -- | 2.00 | -- | 2.29 | -0.2698 | -0.2698 | 0.1408 | 0.1397 | 0.7249 | 1.04 | 95.33 | 137,407.20 | -139.23 | -- | -285.65 | -- | 69.25 | -- | -192.08 | -- | 0.5439 | -- | 0.00 | -- | 123.50 | -- | -138.94 | -- | -- | -- |
Marizyme Inc | 364.96k | -52.51m | 5.65m | 11.00 | -- | -- | -- | 15.49 | -0.974 | -0.974 | 0.004 | -0.0712 | 0.0125 | 1.31 | 10.00 | 33,178.18 | -179.49 | -59.02 | -742.64 | -64.47 | 70.17 | 70.38 | -14,389.19 | -9,435.92 | 0.038 | -0.6989 | 1.92 | -- | 176.59 | 99.98 | -71.22 | -- | -- | -- |
Galmed Pharmaceuticals Ltd | 0.00 | -5.88m | 6.02m | 3.00 | -- | 0.4203 | -- | -- | -24.68 | -24.68 | 0.00 | 22.25 | 0.00 | -- | -- | 0.00 | -44.20 | -45.06 | -52.67 | -50.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 61.31 | -- | -- | -- |
Transcode Therapeutics Inc | 0.00 | -17.91m | 6.06m | 10.00 | -- | 1.93 | -- | -- | -75.48 | -75.48 | 0.00 | 0.182 | 0.00 | -- | -- | 0.00 | -334.48 | -133.14 | -973.00 | -181.26 | -- | -- | -- | -- | -- | -90.11 | 0.00 | -- | -- | -- | -5.59 | -- | -- | -- |
CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 6.11m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
Xenetic Biosciences Inc | 2.52m | -4.70m | 6.12m | 4.00 | -- | 0.8219 | -- | 2.43 | -3.05 | -3.05 | 1.64 | 4.83 | 0.2314 | -- | -- | 630,087.50 | -43.12 | -48.91 | -48.61 | -52.82 | -- | -- | -186.33 | -682.42 | -- | -- | 0.00 | -- | 48.80 | -- | 36.90 | -- | -- | -- |
Alzamend Neuro Inc | 0.00 | -7.39m | 6.57m | 4.00 | -- | -- | -- | -- | -10.69 | -10.69 | 0.00 | -1.41 | 0.00 | -- | -- | 0.00 | -344.10 | -177.86 | -- | -257.81 | -- | -- | -- | -- | -- | -363.62 | -- | -- | -- | -- | 33.14 | -- | -- | -- |
Cardio Diagnostics Holdings Inc | 39.14k | -8.77m | 6.70m | 7.00 | -- | 2.12 | -- | 171.28 | -0.4899 | -0.4899 | 0.0021 | 0.1319 | 0.0073 | -- | 9.13 | 5,591.43 | -163.16 | -- | -268.73 | -- | -- | -- | -22,414.13 | -- | -- | -9.32 | 0.0295 | -- | 1,696.84 | -- | -79.72 | -- | -- | -- |
Adial Pharmaceuticals Inc | 0.00 | -12.19m | 6.72m | 4.00 | -- | 1.05 | -- | -- | -5.26 | -5.30 | 0.00 | 0.9961 | 0.00 | -- | -- | 0.00 | -279.27 | -182.35 | -320.96 | -235.45 | -- | -- | -- | -- | -- | -14.25 | 0.00 | -- | -- | -- | 35.14 | -- | -- | -- |
Moleculin Biotech Inc | 0.00 | -25.17m | 6.74m | 18.00 | -- | 0.3428 | -- | -- | -11.62 | -11.62 | 0.00 | 6.91 | 0.00 | -- | -- | 0.00 | -69.24 | -46.84 | -83.35 | -51.49 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.56 | -- | -21.54 | -- |
Eterna Therapeutics Inc | 162.00k | -23.94m | 6.93m | 8.00 | -- | -- | -- | 42.75 | -4.42 | -4.42 | 0.0299 | -1.58 | 0.0035 | -- | 0.2673 | 20,250.00 | -51.20 | -169.05 | -62.39 | -223.00 | -111.11 | -- | -14,765.43 | -682.61 | -- | -10.12 | 10.22 | -- | -- | -68.89 | 11.84 | -- | -58.86 | -- |
Holder | Shares | % Held |
---|---|---|
3i Management LLCas of 23 Jul 2024 | 1.72m | 9.94% |
UBS Securities LLCas of 30 Jun 2024 | 74.92k | 0.43% |
Geode Capital Management LLCas of 30 Jun 2024 | 38.40k | 0.22% |
Citadel Securities LLCas of 30 Jun 2024 | 25.51k | 0.15% |
G1 Execution Services LLCas of 30 Jun 2024 | 24.25k | 0.14% |
Sheets Smith Wealth Managementas of 30 Jun 2024 | 20.14k | 0.12% |
Virtu Americas LLCas of 30 Jun 2024 | 18.36k | 0.11% |
Private Capital Management LLC (Colorado)as of 30 Jun 2024 | 17.52k | 0.10% |
Two Sigma Securities LLCas of 30 Jun 2024 | 12.85k | 0.07% |
CapFinancial Partners LLCas of 30 Jun 2024 | 11.25k | 0.07% |